Intellectual Property
Idera scientists have extensive experience in the design and creation of novel nucleic acid-based compounds. This pioneering work has led the Company to discover novel compounds that are agonists of Toll-like Receptors, antagonists of Toll-like Receptors, gene silencing oligonucleotides and antisense compounds.
Idera uses a variety of methods to protect its discoveries, including filing U.S. and foreign patent applications for the proprietary technologies, inventions, and improvements that are important to the development of our business. Through the Company’s patent application filings, it has assembled a substantial patent portfolio covering a broad range of DNA and RNA-based technologies. This patent portfolio currently includes over 500 patents and patent applications in countries around the world.
Idera has devoted, and continues to devote, a substantial amount of its resources into establishing intellectual property protection for:
- Nucleic acid-based compounds that function as TLR3, 7, 8 or 9 agonists;
- Nucleic acid-based compounds that function as TLR7 and TLR9 antagonists;
- Gene silencing oligonucleotides;
- Second generation antisense oligonucleotides; and
- Use of our nucleic acid chemistry, nucleic acid-based compounds, gene silencing oligonucleotides or antisense oligonucleotides to treat or prevent a variety of diseases.
In addition to seeking patent protection, the Company relies on trade secrets, know-how, continuous technological innovations, and in-licensing opportunities to develop and maintain our proprietary position.
